Arrowhead Pharmaceuticals’ (ARWR) “Overweight” Rating Reiterated at Piper Jaffray Companies
Piper Jaffray Companies reaffirmed their overweight rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note issued to investors on Monday, The Fly reports. They currently have a $50.00 price objective on the biotechnology company’s stock.
A number of other equities analysts also recently weighed in on ARWR. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday, August 1st. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, September 10th. TheStreet upgraded shares of Arrowhead Pharmaceuticals from a d rating to a c+ rating in a report on Thursday, May 30th. B. Riley boosted their target price on shares of Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the stock a buy rating in a report on Monday, August 19th. Finally, Cantor Fitzgerald cut shares of Arrowhead Pharmaceuticals from an overweight rating to a neutral rating and set a $24.00 price objective for the company. in a research report on Thursday, June 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $36.13.
Shares of ARWR opened at $29.28 on Monday. The company has a market cap of $2.78 billion, a price-to-earnings ratio of -45.05 and a beta of 1.51. Arrowhead Pharmaceuticals has a 1-year low of $10.41 and a 1-year high of $36.80. The company’s fifty day simple moving average is $30.92 and its 200 day simple moving average is $24.57.
In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 85,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $30.00, for a total transaction of $2,550,000.00. Following the completion of the transaction, the director now directly owns 121,000 shares of the company’s stock, valued at $3,630,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael S. Perry sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, September 9th. The stock was sold at an average price of $28.90, for a total transaction of $2,890,000.00. Following the transaction, the director now directly owns 121,000 shares of the company’s stock, valued at $3,496,900. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 202,756 shares of company stock valued at $5,930,243. Company insiders own 4.80% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Aperio Group LLC bought a new position in Arrowhead Pharmaceuticals during the second quarter worth $483,000. JPMorgan Chase & Co. boosted its position in shares of Arrowhead Pharmaceuticals by 3.9% in the second quarter. JPMorgan Chase & Co. now owns 315,152 shares of the biotechnology company’s stock valued at $9,083,000 after acquiring an additional 11,907 shares during the period. Rhumbline Advisers boosted its position in shares of Arrowhead Pharmaceuticals by 7.2% in the first quarter. Rhumbline Advisers now owns 124,276 shares of the biotechnology company’s stock valued at $2,280,000 after acquiring an additional 8,313 shares during the period. Elkfork Partners LLC boosted its position in shares of Arrowhead Pharmaceuticals by 467.6% in the second quarter. Elkfork Partners LLC now owns 13,124 shares of the biotechnology company’s stock valued at $348,000 after acquiring an additional 10,812 shares during the period. Finally, Comerica Bank bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $2,527,000. 71.91% of the stock is owned by hedge funds and other institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Further Reading: Penny Stocks
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.